Eli Lil­ly's Pre­vail strikes po­ten­tial bil­lion-dol­lar AAV cap­sids deal with Sang­amo for neu­ro­log­i­cal dis­eases

Eli Lil­ly’s Pre­vail Ther­a­peu­tics has ex­pand­ed again in­to neu­ro­log­i­cal tar­gets thanks to a po­ten­tial bil­lion-dol­lar deal with Sang­amo Ther­a­peu­tics. The pair will eval­u­ate some of Sang­amo’s ade­no-as­so­ci­at­ed virus (AAV) cap­sids with the po­ten­tial to li­cense the cap­sids for gene ther­a­pies.

The AAV cap­sids were gen­er­at­ed us­ing Sang­amo’s SIFTER plat­form but they’re still ear­ly-stage, ac­cord­ing to the com­pa­ny, show­ing “po­ten­tial” ef­fi­cient de­liv­ery of gene ther­a­pies to the cen­tral ner­vous sys­tem in pre­clin­i­cal an­i­mal mod­els.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER